Continental Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Continental Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$656K	–	56
2022 Q4	$656K	Hold	5,000	–	–	0.34%	56
2022 Q3	$585K	Hold	5,000	–	–	0.34%	54
2022 Q2	$588K	Buy	+5,000	New	+$594K	0.35%	55
2019 Q3	–	Sell	-12,200	Closed	-$1.33M	–	79
2019 Q2	$1.33M	Sell	12,200 -800	-6%	-$85.1K	0.75%	52
2019 Q1	$1.45M	Sell	13,000 -28,500	-69%	-$3.13M	0.68%	56
2018 Q4	$4M	Buy	41,500 +21,500	+108%	+$2.28M	1.22%	29
2018 Q3	$2.44M	Hold	20,000	–	–	0.53%	64
2018 Q2	$2.2M	Buy	+20,000	New	+$2.14M	0.55%	60

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Continental Advisors's IBB Position: Q4 2020 in Review

Continental Advisors sold out of iShares Biotechnology ETF (IBB) in Q4 2020, closing a stake of 5,400 shares — an estimated $731K sold.

Continental Advisors first reported a position in IBB in Q2 2013 and held it in 8 quarters. The position peaked at $2.91M in Q4 2014. 856 funds tracked by Wall St. Rank hold IBB as of Q4 2020.

Continental Advisors reported no remaining iShares Biotechnology ETF position as of Q4 2020 after selling out during the quarter.
Continental Advisors sold 5,400 iShares Biotechnology ETF shares in Q4 2020, an estimated $731K.
Continental Advisors first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 8 quarters.
Continental Advisors's iShares Biotechnology ETF position peaked at $2.91M in Q4 2014.
856 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2020.

Based on Continental Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.